Department of Gastroenterology, The First People's Hospital of Wujiang District Suzhou, Suzhou, China.
Eur Rev Med Pharmacol Sci. 2018 Jun;22(12):4018-4024. doi: 10.26355/eurrev_201806_15288.
To explore the therapeutic effect of Bifidobacterium combined with early enteral nutrition in severe acute pancreatitis.
A total of 60 patients with severe acute pancreatitis admitted from November 2012 to November 2016 were retrospectively analyzed. According to the different treatment methods, the patients were divided into Bifidobacterium combined with early enteral nutrition group (experiment group) and early enteral nutrition group (control group). Serum ALB (albumin), CRP (C-reactive protein), WBC (white blood cell count) and PCT (procalcitonin) levels in both groups were observed. The pain relief time, diet recovery time, length of stay, and hospitalization costs between the two groups, were compared. The APACHE (acute physiology and chronic health evaluation scoring system) II score and SOFA (sequential organ failure assessment) score before and after nutritional support were compared between the two groups. Adverse events and complications were observed as well.
58 patients recovered and 2 died after treatment. Improvements in laboratory indicators such as ALB, CRP, WBC and PCT were much better in the experiment group than the control group (p<0.05). Both the length of days and hospitalization cost were lower in the experiment group than those of the control group (p=0.0029, p=0.0435). In the comparison of hospitalization symptoms, shorter pain relief time and diet recovery time were found in the experiment group than those in the control group (p=0.0003, p=0.0218). After the treatment, APACHE II score and SOFA score of the experiment group were also higher than the control group. No significant differences in adverse events and complications between the two groups were exerted (p>0.05).
Bifidobacterium combined with early enteral nutrition can improve the nutritional status of patients with severe acute pancreatitis in the acute stage, which also enhances the patient's immune capacity and the body's resistance to disease.
探讨双歧杆菌联合早期肠内营养对重症急性胰腺炎的治疗效果。
回顾性分析 2012 年 11 月至 2016 年 11 月收治的 60 例重症急性胰腺炎患者，根据治疗方法不同分为双歧杆菌联合早期肠内营养组（观察组）和早期肠内营养组（对照组）。观察两组患者血清白蛋白（ALB）、C 反应蛋白（CRP）、白细胞计数（WBC）和降钙素原（PCT）水平，比较两组患者疼痛缓解时间、饮食恢复时间、住院时间、住院费用，比较两组患者营养支持前后急性生理学与慢性健康状况评分系统Ⅱ（APACHEⅡ）评分和序贯器官衰竭评估（SOFA）评分，观察两组患者不良反应及并发症发生情况。
治疗后 58 例患者痊愈出院，2 例死亡。观察组患者 ALB、CRP、WBC 和 PCT 等实验室指标改善情况明显优于对照组（p<0.05）。观察组患者的住院时间及住院费用均低于对照组（p=0.0029，p=0.0435）。观察组患者疼痛缓解时间及饮食恢复时间短于对照组（p=0.0003，p=0.0218）。治疗后观察组患者的 APACHEⅡ评分和 SOFA 评分均高于对照组。两组患者不良反应及并发症发生率比较差异无统计学意义（p>0.05）。
双歧杆菌联合早期肠内营养可改善重症急性胰腺炎患者急性期的营养状态，提高患者免疫能力和机体对疾病的抵抗力。
